hepatitis C | oncology | Anadys Pharmaceuticals, Inc.

7/30/2010
Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference

7/29/2010
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24

7/29/2010
Anadys Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights

Anadys Presenting at the Stifel Nicolaus Healthcare Conference
Friday, September 17, 2010 at 11:30am ET

Anadys Presenting at the UBS Global Life Sciences Conference
September 20th-22nd

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non- nucleoside polymerase inhibitor for the treatment of hepatitis C. In an ongoing Phase II study, the Company has completed 12 weeks of dosing ANA598 added to current standard of care. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.		ANA598 - HCV ANA773 - HCV ANA773 - Oncology
Home \| About Us \| Therapeutic Focus \| Development Programs \| Investors \| Careers \| Contact Us Terms of Use \| Privacy Policy \| Site Map © Anadys Pharmaceuticals, Inc.